268 related articles for article (PubMed ID: 25693885)
1. The oncolytic virus, pelareorep, as a novel anticancer agent: a review.
Chakrabarty R; Tran H; Selvaggi G; Hagerman A; Thompson B; Coffey M
Invest New Drugs; 2015 Jun; 33(3):761-74. PubMed ID: 25693885
[TBL] [Abstract][Full Text] [Related]
2. Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats.
Chakrabarty R; Tran H; Boulay I; Moran T; Parenteau A; Tavcar R; Bigras M; Hagerman A; Serl S; Thompson B; Coffey M
Invest New Drugs; 2013 Dec; 31(6):1476-86. PubMed ID: 24121993
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of REOLYSIN
Mahalingam D; Fountzilas C; Moseley J; Noronha N; Tran H; Chakrabarty R; Selvaggi G; Coffey M; Thompson B; Sarantopoulos J
Cancer Chemother Pharmacol; 2017 Apr; 79(4):697-703. PubMed ID: 28289863
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Study of Pelareorep (REOLYSIN
Mahalingam D; Goel S; Aparo S; Patel Arora S; Noronha N; Tran H; Chakrabarty R; Selvaggi G; Gutierrez A; Coffey M; Nawrocki ST; Nuovo G; Mita MM
Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29799479
[TBL] [Abstract][Full Text] [Related]
5. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
Kapadia R; Coffey MC
Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of homogeneity and genetic stability of REOLYSIN (pelareorep) by complete genome sequencing of reovirus after large scale production.
Chakrabarty R; Tran H; Fortin Y; Yu Z; Shen SH; Kolman J; Onions D; Voyer R; Hagerman A; Serl S; Kamen A; Thompson B; Coffey M
Appl Microbiol Biotechnol; 2014 Feb; 98(4):1763-70. PubMed ID: 24419798
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.
Groeneveldt C; Kinderman P; Griffioen L; Rensing O; Labrie C; van den Wollenberg DJM; Hoeben RC; Coffey M; Loghmani H; Verdegaal EME; Welters MJP; van der Burg SH; van Hall T; van Montfoort N
Cancer Immunol Res; 2024 Mar; 12(3):334-349. PubMed ID: 38194598
[TBL] [Abstract][Full Text] [Related]
8. GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers.
Collienne M; Loghmani H; Heineman TC; Arnold D
Future Oncol; 2022 Aug; 18(26):2871-2878. PubMed ID: 35796248
[TBL] [Abstract][Full Text] [Related]
9. Reovirus therapy in cancer: has the orphan virus found a home?
Yap TA; Brunetto A; Pandha H; Harrington K; Debono JS
Expert Opin Investig Drugs; 2008 Dec; 17(12):1925-35. PubMed ID: 19012507
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic viral therapy using reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2009; 542():607-34. PubMed ID: 19565924
[TBL] [Abstract][Full Text] [Related]
11. Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma.
Islam S; Espitia CM; Persky DO; Carew JS; Nawrocki ST
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372612
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.
Gong J; Sachdev E; Mita AC; Mita MM
World J Methodol; 2016 Mar; 6(1):25-42. PubMed ID: 27019795
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Viral Therapy Using Reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2015; 1317():187-223. PubMed ID: 26072409
[TBL] [Abstract][Full Text] [Related]
14. Reovirus-based therapy for cancer.
Kelly K; Nawrocki S; Mita A; Coffey M; Giles FJ; Mita M
Expert Opin Biol Ther; 2009 Jul; 9(7):817-30. PubMed ID: 19527106
[TBL] [Abstract][Full Text] [Related]
15. Connecting reovirus oncolysis and Ras signaling.
Marcato P; Shmulevitz M; Lee PW
Cell Cycle; 2005 Apr; 4(4):556-9. PubMed ID: 15753655
[TBL] [Abstract][Full Text] [Related]
16. Reovirus: Rationale and clinical trial update.
Lal R; Harris D; Postel-Vinay S; de Bono J
Curr Opin Mol Ther; 2009 Oct; 11(5):532-9. PubMed ID: 19806501
[TBL] [Abstract][Full Text] [Related]
17. Reovirus - possible therapy of cancer.
Figova K; Hrabeta J; Eckschlager T
Neoplasma; 2006; 53(6):457-62. PubMed ID: 17167712
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas.
Carew JS; Espitia CM; Zhao W; Mita MM; Mita AC; Nawrocki ST
Oncotarget; 2017 Oct; 8(49):86769-86783. PubMed ID: 29156834
[TBL] [Abstract][Full Text] [Related]
19. Reovirus and tumor oncolysis.
Kim M; Chung YH; Johnston RN
J Microbiol; 2007 Jun; 45(3):187-92. PubMed ID: 17618222
[TBL] [Abstract][Full Text] [Related]
20. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
Morris DG; Feng X; DiFrancesco LM; Fonseca K; Forsyth PA; Paterson AH; Coffey MC; Thompson B
Invest New Drugs; 2013 Jun; 31(3):696-706. PubMed ID: 22886613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
